23rd Jun 2026 07:00
Result of AGM
LONDON and PHILADELPHIA - June 23, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces that all resolutions were duly passed by shareholders at the Annual General Meeting (AGM), which was held on Monday June 22.
The results of the voting at the AGM are outlined in the table below and the presentation materials are available on the Company's website here.
| For | Against | Withheld | ||
Resolution | Votes | % | Votes | % | Votes |
1 | 52,701,858 | 99.98% | 8,684 | 0.02% | 4,914,991 |
2 | 52,103,657 | 99.94% | 31,899 | 0.06% | 5,489,977 |
3 | 57,460,173 | 99.97% | 15,205 | 0.03% | 150,155 |
4 | 57,430,906 | 99.98% | 13,310 | 0.02% | 181,317 |
5 | 57,427,007 | 99.98% | 14,310 | 0.02% | 184,216 |
6 | 57,442,445 | 99.98% | 11,871 | 0.02% | 171,217 |
7 | 55,827,845 | 97.19% | 1,612,782 | 2.81% | 184,906 |
8 | 57,318,857 | 99.98% | 11,486 | 0.02% | 295,190 |
9 | 57,455,176 | 99.98% | 9,947 | 0.02% | 160,410 |
10 | 56,788,798 | 99.69% | 177,925 | 0.31% | 658,810 |
11 | 56,516,332 | 99.22% | 446,550 | 0.78% | 662,651 |
12 | 56,524,420 | 99.23% | 436,265 | 0.77% | 664,848 |
13 | 57,104,150 | 99.55% | 258,807 | 0.45% | 262,576 |
-Ends-
For further information from Avacta, please contact:
Avacta Group plc Christina Coughlin, Chief Executive Officer | https://avacta.com/ via Cohesion Bureau |
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance
| www.strandhanson.co.uk
|
Zeus (Broker) James Hornigold / George Duxberry / Dominic King
| www.zeuscapital.co.uk |
Cohesion Bureau Communications / Media / Investors Richard Jarvis
|
|
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.
Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma.
Related Shares:
Avacta Group